A higher responder rate was observed in the patients with low CXCL5 expression levels compared with high expression levels, but the difference was statistically insignificant due to the limited sample size, suggesting that CXCL5 expression might be a potential predictive and prognostic biomarker for immunotherapy in NSCLC. The gene discussed is CXCL5; the disease is non-small cell lung carcinoma.